Constipation-Predominant IBS Beyond Fiber: Choosing a Secretagogue
A single patient with constipation-predominant irritable bowel syndrome unresponsive to fiber and osmotic laxatives, testing which secretagogue actually fits her specific symptom pattern rather than defaulting to whichever is prescribed most often.
Naomi V., a 38-year-old woman who works as a software project manager, has struggled with constipation-predominant IBS for about five years, symptoms that flare predictably during her team's quarterly release crunches and never fully resolve in between. She's tried increasing dietary fiber, a fiber supplement, and polyethylene glycol at an adequate daily dose for the last four months, with only modest improvement — still going three to four days between bowel movements, with bloating and lower abdominal discomfort that hasn't budged much regardless of how consistently she takes the PEG. She's candid about her main hesitation moving to a prescription option: a college roommate once described a bad reaction to a bowel medication in enough detail that Naomi has genuinely been putting off this conversation for months out of fear of losing control in the other direction.
That hesitation is worth taking seriously as a real clinical input, not just an anxiety to talk her past, because the two most-prescribed IBS-C drugs in her actual drug class differ in exactly the dimension she's worried about. Linaclotide and plecanatide are both guanylate cyclase-C agonists, working by increasing intestinal fluid secretion and accelerating transit, and both have real trial evidence for improving not just bowel frequency but abdominal pain specifically — a genuine advantage over a plain osmotic laxative like the PEG she's already maximized, which moves stool without doing much for visceral pain. Where they diverge is tolerability, and the numbers are not close. In linaclotide's phase 3 IBS-C trials (Chey et al. and Rao et al., 2012) diarrhea was reported by roughly one patient in five — generally dose-related and manageable, but easily the most-reported adverse effect. In plecanatide's (Brenner et al., 2018) it ran around four percent. That is the difference between a side effect Naomi would probably encounter and one she probably wouldn't, which matters more for her than a tolerability footnote usually would, because the side effect in question is the specific thing that has kept her from filling a prescription for months.
Clinic, choosing a secretagogue
I'd start linaclotide. It has the most extensive trial base of any IBS-C drug in this class — Chey and Rao's phase 3 trials both hit co-primary endpoints — and critically, it's shown to improve abdominal pain, not just bowel frequency — something plain PEG, which she's already maximized, doesn't reliably address. That dual benefit matters directly for Naomi, since bloating and discomfort are as much a part of her complaint as the constipation itself.
I hear the case for linaclotide, but I want her stated fear of diarrhea taken seriously as a real clinical input, not just something to talk her past. Brenner's phase 3 plecanatide trials reported diarrhea in roughly four percent of patients against the roughly one in five in linaclotide's. Given that this is the exact thing standing between her and starting a prescription at all, I'd start there instead.
Both drugs work through the same mechanism, guanylate cyclase-C agonism, so the choice between them genuinely does come down to the tolerability difference you're both naming, and I don't think that's a small consideration — a patient who starts a drug she's afraid of and stops at the first loose stool gets no benefit from either option's efficacy data. I'd start plecanatide given how explicitly she's named this fear, with a clear plan to switch to linaclotide if her pain control specifically doesn't improve enough, since linaclotide's larger trial base gives more confidence on that particular outcome. And worth naming for the record: if diarrhea turns out to be a problem with either GC-C agonist, lubiprostone is a genuinely different mechanism, chloride channel activation rather than guanylate cyclase stimulation, with its own tradeoff (nausea, not diarrhea) rather than more of the same side effect under a different drug name.
Agreed: plecanatide 3mg daily started with PEG discontinued, a two-week check-in scheduled specifically to assess both bowel frequency and abdominal pain separately, and an explicit plan documented to switch to linaclotide if pain control is inadequate despite improved bowel habits, rather than assuming one drug's success on frequency automatically means success on the symptom that brought her in.